New Joint Venture Formed to Provide DNA Testing in HBDC Market | GenomeWeb

NEW YORK (GenomeWeb News) – Co-Diagnostics and DNA Logix have created a joint venture to tackle infectious diseases in high-burden developing countries.

The venture, called Co-Diagnostics HBDC, will sell testing products and services based on PCR testing technology developed by DNA Logix to HBDCs. Co-Diagnostics HBDC is licensing the technology specifically for the HBDC market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.